Global vaccine companies are also developing 'Omicron customized' vaccines while examining the effectiveness of existing vaccines in relation to the mutation of Omicron for COVID-19.
Pfizer CEO Albert Bulla said, "We don't know yet, but we believe there is a possibility that the protection of existing vaccines may be reduced."
Pfizer created a new DNA template on the 26th as the first step in vaccine development.
Moderna's chief medical officer, Paul Burton, was also concerned, citing a possible link between omicron mutations and 'immune evasion'.
"If there is a need to make a new vaccine, we will be able to release a vaccine early next year before mass production," he predicted.
"It will be several months before we are ready to mass-produce and supply a vaccine against a specific mutation called Omicron," Moderna CEO Stefan Bansel told CNBC.
Although he believes that the omicron mutation is highly contagious, he said it would take at least two weeks to determine how much the mutation would affect the effectiveness of vaccines currently available.
Johnson & Johnson, which developed the Janssen vaccine, is also evaluating the effectiveness of the existing vaccine, and said that if necessary, it will start work on developing a vaccine against Omicron.